Related Experiment Video
Updated: Jul 25, 2025

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
Immune Thrombocytopenia: A Rare Adverse Event of Vancomycin Therapy
Emeka S Obi1, Devdat Lnu2,3, Norense O Ehimwenma4
1Department of Health Administration, College of Public Health, East Tennessee State University, Johnson City, USA.
Abstract:
Vancomycin, a glycopeptide antibiotic, is widely used for Gram-positive cocci or bacilli bacteria-induced serious infections. Although considered safe and effective, it still causes adverse events. Vancomycin-induced immune thrombocytopenia is a rarely reported adverse event, manifesting from asymptomatic thrombocytopenia to life-threatening bleeding. We underline a case of a 56-year-old male with a diabetic foot with an infected exudating purulent ulcer. He experienced a significant drop in platelet count after commencing vancomycin, and discontinuing vancomycin resulted in improved platelet count with positive vancomycin-induced anti-platelet antibodies. After ruling out other possible causes of thrombocytopenia, a presumptive diagnosis of vancomycin-induced thrombocytopenia was made.
Insights
Vancomycin, an antibiotic for serious infections, can rarely cause immune thrombocytopenia, a drop in platelet count. This case highlights the importance of monitoring platelet levels during vancomycin treatment.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Vancomycin is a critical glycopeptide antibiotic for severe Gram-positive bacterial infections.
- Adverse events, though uncommon, can occur with vancomycin therapy.
- Immune thrombocytopenia is a rare but serious potential side effect.
Observation:
- A 56-year-old male with a diabetic foot ulcer developed a severe drop in platelet count after starting vancomycin.
- Platelet levels improved significantly upon vancomycin discontinuation.
- Testing confirmed the presence of vancomycin-induced anti-platelet antibodies.
Findings:
- The patient's thrombocytopenia was directly linked to vancomycin administration.
- Exclusion of other causes supported the diagnosis of vancomycin-induced immune thrombocytopenia.
- This case confirms a rare adverse drug reaction to vancomycin.
Implications:
- Clinicians should consider vancomycin-induced immune thrombocytopenia in patients presenting with unexplained thrombocytopenia.
- Monitoring platelet counts is crucial during vancomycin therapy, especially in high-risk patients.
- Early recognition and drug withdrawal can prevent severe bleeding complications.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Myocarditis III: Medical Management
Venous Thrombosis IV: Nursing Management
Endocarditis IV: Nursing Management
Endocarditis III: Medical Management

